Drug profile · INN
anifrolimab-fnia
SAPHNELO
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
anifrolimab-fnia (SAPHNELO) is an FDA-listed pharmaceutical active ingredient. Route of administration: single-use. Current US regulatory status: approved.
Key facts
INN anifrolimab-fnia
Brand SAPHNELO
Route SINGLE-USE
Formulation VIAL
Frequently asked questions
What is anifrolimab-fnia?
anifrolimab-fnia (SAPHNELO) is an FDA-listed pharmaceutical active ingredient. Route of administration: single-use. Current US regulatory status: approved.
What is the brand name for anifrolimab-fnia?
SAPHNELO is a marketed brand name for anifrolimab-fnia. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of anifrolimab-fnia?
anifrolimab-fnia has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.